Form 4: HealthEquity Executive Sells Shares Under 10b5-1 Plan
Insider Transaction Report
HealthEquity Inc. executive Michael Fiore reported a transaction involving the sale of common stock, executed under a pre-arranged trading plan.
Summary
- Michael Fiore, EVP, Chief Commercial Officer at HealthEquity, Inc., reported a sale of 2,470 shares of common stock on July 2, 2026.
- The transaction was executed at a price of $95 per share.
- Following this transaction, Fiore beneficially owns 56,643 shares of HealthEquity common stock.
- The sale was made pursuant to a Rule 10b5-1 trading plan adopted by Fiore on October 14, 2025.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing. While an executive sale can be a negative signal, the execution under a Rule 10b5-1 plan mitigates concerns about insider trading and suggests a pre-planned financial decision rather than a reaction to company performance.
Negatives
- Executive selling company stock can sometimes be perceived negatively by the market, though this sale was conducted under a pre-established trading plan.
Risks
- The Rule 10b5-1 trading plan is designed to mitigate insider trading concerns, but the execution of sales can still be interpreted by the market as a signal of the executive's outlook on the stock's future performance.
Future Outlook
The filing itself does not contain forward-looking statements or guidance regarding the company's future performance. It solely reports a past transaction.
Industry Context
StockSavvy.ai notes that insider sales, even under Rule 10b5-1 plans, are common in the health savings account and benefits administration industry as executives manage their personal portfolios. The key is the adherence to pre-defined plans to avoid perceptions of opportunistic trading.
Stakeholder Impact
- Shareholders: The sale by an executive might be viewed with caution, but the adherence to a 10b5-1 plan suggests it's a pre-determined transaction, potentially limiting negative sentiment.
Key Dates
| Date | Description |
|---|---|
| 10/14/2025 | Date the Rule 10b5-1 trading plan was adopted by Michael Fiore. |
| 07/02/2026 | Date of the reported stock transaction (sale). |
| 07/07/2026 | Date the Form 4 was signed by the reporting person. |
Keywords
HealthEquity, HQY, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Executive Compensation, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.